Managing Nonmetastatic Castration-resistant Prostate Cancer

Slides:



Advertisements
Similar presentations
Volume 69, Issue 5, Pages (May 2016)
Advertisements

Volume 64, Issue 5, Pages (November 2013)
European Journal of Cancer
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017  Silke Gillessen, Gerhardt.
Volume 60, Issue 2, Pages (August 2011)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 70, Issue 4, Pages (October 2016)
Testosterone Therapy in Men With Prostate Cancer
David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono 
European Urology Focus
Volume 68, Issue 6, Pages e129-e131 (December 2015)
Volume 61, Issue 6, Pages (June 2012)
Volume 73, Issue 2, Pages (February 2018)
Volume 70, Issue 1, Pages (July 2016)
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A
Volume 68, Issue 4, Pages (October 2015)
Volume 66, Issue 5, Pages (November 2014)
Volume 73, Issue 5, Pages (May 2018)
Volume 74, Issue 2, Pages (August 2018)
Volume 54, Issue 4, Pages (October 2008)
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.
Volume 69, Issue 5, Pages (May 2016)
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology  Philipp.
Volume 65, Issue 6, Pages (June 2014)
Volume 70, Issue 4, Pages (October 2016)
Volume 68, Issue 4, Pages (October 2015)
Volume 68, Issue 1, Pages (July 2015)
Volume 65, Issue 5, Pages (May 2014)
Volume 64, Issue 5, Pages (November 2013)
Volume 71, Issue 1, Pages 1-3 (January 2017)
Volume 70, Issue 4, Pages (October 2016)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Prostate Cancer Detection: A View of the Future
Volume 65, Issue 4, Pages (April 2014)
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 66, Issue 3, Pages (September 2014)
Volume 62, Issue 1, Pages (July 2012)
Volume 66, Issue 5, Pages (November 2014)
Volume 70, Issue 5, Pages (November 2016)
Volume 73, Issue 6, Pages (June 2018)
99mTechnetium-based Prostate-specific Membrane Antigen–radioguided Surgery in Recurrent Prostate Cancer  Tobias Maurer, Stephanie Robu, Margret Schottelius,
Laurent Boccon-Gibod  European Urology Supplements 
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers  Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 61, Issue 6, Pages (June 2012)
Volume 72, Issue 1, Pages (July 2017)
PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging Studies  Steven P. Rowe, Kenneth J.
European Urology Oncology
RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer  Matthew R. Smith  European Urology Supplements 
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Volume 73, Issue 5, Pages (May 2018)
Volume 75, Issue 1, Pages (January 2019)
Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis
Volume 66, Issue 6, Pages (December 2014)
Volume 71, Issue 4, Pages (April 2017)
European Urology Oncology
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Volume 69, Issue 5, Pages (May 2016)
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Axel Heidenreich  European Urology Supplements 
Improving Flexibility and Quality of Life for Your Patients: A Must?
European Urology Oncology
Volume 68, Issue 5, Pages (November 2015)
Highlighting Unmet Needs: Real Patients, Difficult Choices
Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson 
European Urology Oncology
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis  Sarah Burdett, Liselotte M. Boevé,
Axel Heidenreich  European Urology Supplements 
Salvage Local Treatments After Focal Therapy for Prostate Cancer
European Urology Oncology
Presentation transcript:

Managing Nonmetastatic Castration-resistant Prostate Cancer Joaquin Mateo, Karim Fizazi, Silke Gillessen, Axel Heidenreich, Raquel Perez-Lopez, Wim J.G. Oyen, Neal Shore, Matthew Smith, Christopher Sweeney, Bertrand Tombal, Scott A. Tomlins, Johann S. de Bono  European Urology  DOI: 10.1016/j.eururo.2018.07.035 Copyright © 2018 The Authors Terms and Conditions

Fig. 1 Schematic representation of disease evolution patterns to the clinical states of nonmetastatic castration-resistant prostate cancer (nmCRPC). ADT=androgen deprivation therapy; BS=bone scintigraphy; CT=computerised tomography; HNPC=hormone-naïve prostate cancer; CRPC=castration-resistant prostate cancer; mCRPC=metastatic castration-resistant prostate cancer; PC=prostate cancer; PSA=prostate specific antigen. European Urology DOI: (10.1016/j.eururo.2018.07.035) Copyright © 2018 The Authors Terms and Conditions

Fig. 2 Axial section of Ga-68-PSMA-PET (A) identifying a small sacral bone metastasis in a patient with rising PSA on ADT with no metastatic disease detected by CT (B) or bone scan. (C) PET/CT fusion images, with the arrow pointing at the metastatic deposit. CT=computed tomography; PET=positron emission tomography; PSA=prostate specific antigen; PSMA=prostate-specific membrane antigen. European Urology DOI: (10.1016/j.eururo.2018.07.035) Copyright © 2018 The Authors Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.